Investor Alert Issued in Ardelyx, Inc. Securities Fraud Class Action
Pomerantz LLP has filed a class action lawsuit against Ardelyx, Inc., alleging securities fraud and unlawful business practices by the company and its officers.
A class action lawsuit has been filed against Ardelyx, Inc. (NASDAQ: ARDX) by Pomerantz LLP. The suit alleges that Ardelyx and certain of its officers and/or directors engaged in securities fraud or other unlawful business practices. Investors who purchased Ardelyx securities during the class period and suffered losses are advised to contact Pomerantz LLP.
The deadline for investors to seek appointment as Lead Plaintiff is November 16, 2026. The lawsuit stems from Ardelyx's August 6, 2026 press release, in which the company reduced its full-year 2026 revenue guidance for IBSRELA and withdrew its long-term revenue guidance for XPHOZAH. The company cited increased payer utilization-management processes restricting patient access to IBSRELA and "evolving market dynamics" for XPHOZAH.
Following this news, Ardelyx's stock price dropped by $0.87 per share, or 17.86%, to close at $4.00 per share on August 7, 2026. Pomerantz LLP, a law firm specializing in corporate and securities litigation, is seeking investors to join the class action.
Ardelyx, a biopharmaceutical company focused on addressing underserved medical needs, faces scrutiny over its financial disclosures and commercial performance. The outcome of this class action lawsuit could significantly impact the company's future operations and investor confidence.